Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy

Authors :: Olivier Spertini
Frédéric Lamoth
Dionysios Neofytos
O. Marchetti
Thierry Calandra
Anne-Sophie Brunel
Pierre-Yves Bochud
Agnieszka Wójtowicz
Source :: Haematologica, Vol. 103, No 11 (2018) pp. e527-e530
Publication Year :: 2018
Publisher :: Ferrata Storti Foundation, 2018.
Abstract: Invasive mold infections are a major concern in oncohematologic patients, with incidence and mortality rates ranging between 15–30%.[1][1] While mold-active prophylaxis is recommended during induction chemotherapy for acute leukemia, its universal use has been challenged based on the large number

Subjects :: 0301 basic medicine
Oncology
Adult
Male
medicine.medical_specialty
Anemia, Refractory, with Excess of Blasts/drug therapy/genetics/microbiology
Single-nucleotide polymorphism
Intensive chemotherapy
Aspergillosis/chemically induced/genetics
Polymorphism, Single Nucleotide
03 medical and health sciences
Neoplasm Proteins/genetics
Internal medicine
medicine
Aspergillosis
Humans
Leukemia, Myeloid, Acute/drug therapy/genetics/microbiology
Online Only Articles
Pentraxin-3
ddc:616
Acute leukemia
Anemia, Refractory, with Excess of Blasts
business.industry
Incidence (epidemiology)
Mortality rate
Induction chemotherapy
Hematology
PTX3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasm Proteins
Leukemia, Myeloid, Acute
Serum Amyloid P-Component
030104 developmental biology
C-Reactive Protein
Serum Amyloid P-Component/genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/genetics/microbiology
Female
C-Reactive Protein/genetics
business

Tools